Tower Research Capital (TRC)’s Cyclo Therapeutics, Inc. Common Stock CYTH Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q1 | – | Sell |
-6,684
| Closed | -$3.94K | – | 5983 |
|
|
2024
Q4 | $3.94K | Buy |
6,684
+1,289
| +24% | +$894 | ﹤0.01% | 4559 |
|
|
2024
Q3 | $4.26K | Buy |
5,395
+396
| +8% | +$396 | ﹤0.01% | 4622 |
|
|
2024
Q2 | $6.35K | Sell |
4,999
-1,583
| -24% | -$2.09K | ﹤0.01% | 4589 |
|
|
2024
Q1 | $9.15K | Buy |
6,582
+711
| +12% | +$1.18K | ﹤0.01% | 3887 |
|
|
2023
Q4 | $9.34K | Sell |
5,871
-896
| -13% | -$1.14K | ﹤0.01% | 4404 |
|
|
2023
Q3 | $9.61K | Sell |
6,767
-370
| -5% | -$569 | ﹤0.01% | 4201 |
|
|
2023
Q2 | $11.3K | Sell |
7,137
-4,816
| -40% | -$6.15K | ﹤0.01% | 3987 |
|
|
2023
Q1 | $10K | Buy |
11,953
+7,168
| +150% | +$10.2K | ﹤0.01% | 4421 |
|
|
2022
Q4 | $7K | Buy |
4,785
+205
| +4% | +$339 | ﹤0.01% | 4640 |
|
|
2022
Q3 | $9K | Buy |
4,580
+2,310
| +102% | +$4.84K | ﹤0.01% | 4712 |
|
|
2022
Q2 | $4K | Buy |
2,270
+762
| +51% | +$1.85K | ﹤0.01% | 5275 |
|
|
2022
Q1 | $5K | Buy |
1,508
+836
| +124% | +$2.92K | ﹤0.01% | 5129 |
|
|
2021
Q4 | $3K | Sell |
672
-482
| -42% | -$2.73K | ﹤0.01% | 5516 |
|
|
2021
Q3 | $8K | Buy |
1,154
+589
| +104% | +$4.61K | ﹤0.01% | 4578 |
|
|
2021
Q2 | $6K | Buy |
565
+371
| +191% | +$3.11K | ﹤0.01% | 4650 |
|
|
2021
Q1 | $2K | Buy |
+194
| New | +$1.62K | ﹤0.01% | 5064 |
|
Tower Research Capital (TRC)'s CYTH Position: Q1 2025 in Review
Tower Research Capital (TRC) sold out of Cyclo Therapeutics, Inc. Common Stock (CYTH) in Q1 2025, closing a stake of 6,684 shares — an estimated $3.94K sold.
Tower Research Capital (TRC) first reported a position in CYTH in Q1 2021 and held it in 16 quarters. The position peaked at $11.3K in Q2 2023. 0 funds tracked by Wall St. Rank hold CYTH as of Q1 2025.
- Tower Research Capital (TRC) reported no remaining Cyclo Therapeutics, Inc. Common Stock position as of Q1 2025 after selling out during the quarter.
- Tower Research Capital (TRC) sold 6,684 Cyclo Therapeutics, Inc. Common Stock shares in Q1 2025, an estimated $3.94K.
- Tower Research Capital (TRC) first reported a position in Cyclo Therapeutics, Inc. Common Stock in Q1 2021 and held it in 16 quarters.
- Tower Research Capital (TRC)'s Cyclo Therapeutics, Inc. Common Stock position peaked at $11.3K in Q2 2023.
- 0 funds tracked by Wall St. Rank held Cyclo Therapeutics, Inc. Common Stock as of Q1 2025.
Based on Tower Research Capital (TRC)'s 13F filing for Q1 2025, filed 15 May 2025.